Article Information
- December 7, 2024.
Article Versions
- Version 1 (July 11, 2024 - 12:54).
- You are viewing Version 2, the most recent version of this article.
REVISION SUMMARY
↵* Shared authorship
We conducted additional analyses using an independently acquired sample of individuals with schizophrenia. Remarkably, we observed the same results as in our primary cohort, strengthening the robustness of our findings. Here are the 3 key highlights of our work: 1)Identification of a reproducible cerebellum VTA anticoactivation pattern (r = 0.98) in bilateral paravermal Crus I/II across two distinct recordings at baseline and 3 months (Cohort in Geneva, Switzerland). 2)Clinical relevance of this pattern: lower anticoactivation emergence (i.e., how often the pattern is encountered) at baseline correlated with more severe apathy, particularly asociality and avolition. At 3 months, lower anticoactivation persistence (i.e., how long the pattern lasted) was associated with greater apathy, especially anhedonia, and predicted increased anhedonia at 9 months. Similarly, reduced anticoactivation emergence at 3 months predicted worse asociality at 9 months while reduced persistence at 3 months related to worse anhedonia at 9 months 3)Validation in an independent cohort (Cohort in Berlin, Germany): we identify this pattern with a spatial similarity to the pattern identified in the main cohort of r = 0.93 and we replicate the association of the pattern emergence with apathy, particularly asociality. Please refer to the Validation dataset analyses part. Figures are updated: Former Figure 1 has been moved to the Supplemental Materials. Figure 2 is now Figure 1, with updates to panels B and C. Figure 3 is now Figure 2, with updates to panels C and D. Figure 4 is now Figure 3, with an added panel B. A new Figure 4 has been created to illustrate the additional analyses on validation cohort. Supplemental materials are also updated, with additional analyses.
Author Information
- Farnaz Delavari1,2,*,
- Jade Awada3,*,
- Thomas A. W. Bolton3,
- Fares Alouf3,
- Fabien Carruzzo6,
- Noemie Kuenzi6,
- Mariia Kaliuzhna6,
- Tal Geffen7,
- Teresa Katthagen7,
- Florian Schlagenhauf7,
- Dimitri Van De Ville4,5,
- Stephan Eliez1,
- Stefan Kaiser6,8 and
- Indrit Bègue3,8,#
- 1Developmental Imaging and Psychopathology Laboratory, University of Geneva School of Medicine, Geneva, Switzerland
- 2Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Switzerland
- 3Neuroimaging and translational psychiatry lab, Department of psychiatry, University of Geneva, Switzerland
- 4Institute of Bioengineering, Ecole Polytechnique de Fédérale de Lausanne (EPFL), Lausanne, Switzerland
- 5Department of radiology and medical informatics, University of Geneva, Switzerland
- 6Laboratory for experimental psychopathology, Department of psychiatry, University of Geneva, Switzerland
- 7Department of Psychiatry and Neurosciences, Campus Charité Mitte, Berlin, Germany
- 8Adult psychiatry division, Department of psychiatry, University Hospitals of Geneva, Switzerland
- ↵#Corresponding author: Indrit Bègue, indrit.begue{at}unige.ch, Laboratory for neuroimaging and translational psychiatry, Department of psychiatry, University of Geneva, Switzerland Campus Biotech, Chemin des Mines 9, 1202, Geneva Switzerland